📄 SCRIBE THERAPEUTICS, INC.

Scribe Therapeutics is a clinical-stage biotechnology company engineering in vivo CRISPR technologies to extend healthy lifespan through disease prevention and durable therapeutic intervention. The company focuses on cardiovascular and metabolic diseases, with its lead candidate STX-1150 designed to durably lower LDL-C via epigenetic silencing without permanent DNA changes. Scribe employs a full-stack engineering approach called CRISPR by Design to optimize its technologies for broad patient populations. Key risk: Limited operating history with no completed clinical trials or approved products, making future viability difficult to assess. Proceeds: Advance development of lead product candidate STX-1150, Advance development of additional product candidates STX-1200 and STX-1400, Continued investment in pipeline programs, CRISPR-based technologies (ELXR and XE), and new technology development, Working capital and general corporate purposes, Potential in-license, acquisition, or investm

Scribe Therapeutics is a clinical-stage biotechnology company engineering in vivo CRISPR technologies to extend healthy lifespan through disease prevention and durable therapeutic intervention. The company focuses on cardiovascular and metabolic diseases, with its lead candidate STX-1150 designed to durably lower LDL-C via epigenetic silencing without permanent DNA changes. Scribe employs a full-stack engineering approach called CRISPR by Design to optimize its technologies for broad patient populations.